Life Factors and Melanoma: From the Macroscopic State to the Molecular Mechanism
Source abstract
Abstract
Abstract Melanoma, a highly aggressive form of skin cancer, is shaped by a complex interplay of genetic, environmental, and lifestyle factors. This review provides a comprehensive synthesis of the macroscopic and molecular mechanisms through which various factors such as gender, age, obesity, smoking, alcohol consumption, diet and nutrients, exercise, ultraviolet (UV) exposure, circadian rhythms, and commonly used medications (e.g., steroids, metformin, non‐steroidal anti‐inflammatory drugs [NSAIDs], and antihistamines), impact melanoma risk, progression, and outcomes. To facilitate a more systematic understanding of melanoma risk and pathogenesis, a comprehensive framework is proposed that delineates these factors into four major categories: intrinsic host characteristics, pharmacological influences, metabolic conditions, and behavioral risk profiles. Within each category, these elements interact at the molecular level, collectively influencing the initiation and progression of melanoma. Furthermore, the translational implications of these findings are evaluated, offering actionable insights for prevention and therapeutic strategies in clinical practice. This review aims to bridge the gap between molecular research and real‐world behavioral determinants, providing a holistic framework that advances our understanding of melanoma pathogenesis and supports the development of improved clinical outcomes.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Skin Protection and Aging · Cutaneous Melanoma Detection and Management · Circadian rhythm and melatonin
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Dermatology Xijing Hospital Fourth Military Medical University No 127 of West Changle Road Xi'an Shaanxi 710032 China
Funding
National Natural Science Foundation of China · Key Research and Development Projects of Shaanxi Province
References (100+)
Show source-provided references
1. 10.1038/nrdp.2015.310.1038/nrdp.2015.3 ↗
2. 10.1038/s41392-021-00827-610.1038/s41392-021-00827-6 ↗
3. 10.1016/S0140-6736(23)00821-810.1016/S0140-6736(23)00821-8 ↗
4. 10.1158/1055-9965.EPI-20-003610.1158/1055-9965.EPI-20-0036 ↗
5. 10.1007/s13402-011-0013-010.1007/s13402-011-0013-0 ↗
6. 10.1158/0008-5472.CAN-18-221910.1158/0008-5472.CAN-18-2219 ↗
7. 10.1093/annonc/mdz41410.1093/annonc/mdz414 ↗
8. 10.1016/j.jtcvs.2004.05.02510.1016/j.jtcvs.2004.05.025 ↗
9. 10.1002/ijc.3082710.1002/ijc.30827 ↗
10. 10.1093/neuonc/noaa21810.1093/neuonc/noaa218 ↗
11. 10.1093/jncics/pkaa07810.1093/jncics/pkaa078 ↗
12. 10.1016/j.ejca.2021.04.02910.1016/j.ejca.2021.04.029 ↗
13. 10.1002/ijc.3276410.1002/ijc.32764 ↗
14. 10.1001/jamadermatol.2020.047010.1001/jamadermatol.2020.0470 ↗
15. 10.1089/jwh.2021.022310.1089/jwh.2021.0223 ↗
16. 10.1111/jdv.1698310.1111/jdv.16983 ↗
17. 10.1016/j.lanepe.2021.10002410.1016/j.lanepe.2021.100024 ↗
18. 10.1111/bjd.1551010.1111/bjd.15510 ↗
19. 10.1002/ijc.3040710.1002/ijc.30407 ↗
20. 10.7717/peerj.280910.7717/peerj.2809 ↗
21. 10.1016/j.jaad.2019.09.02910.1016/j.jaad.2019.09.029 ↗
22. Kooij M. K. · Cancers (Basel) · 2021 · 13
23. 10.1056/NEJMoa190405910.1056/NEJMoa1904059 ↗
24. 10.1093/annonc/mdu57310.1093/annonc/mdu573 ↗
25. 10.1038/bjc.2017.7010.1038/bjc.2017.70 ↗
26. 10.1002/ijc.3181310.1002/ijc.31813 ↗
27. 10.1016/j.ijwd.2017.02.00310.1016/j.ijwd.2017.02.003 ↗
28. 10.1111/bjd.1912810.1111/bjd.19128 ↗
29. 10.1093/jnci/djv22110.1093/jnci/djv221 ↗
30. Laffont S. · Front Immunol · 2017 · 8 · 108
31. 10.1007/978-1-4939-3127-9_110.1007/978-1-4939-3127-9_1 ↗
32. 10.1016/j.cbi.2017.09.01710.1016/j.cbi.2017.09.017 ↗
33. 10.1158/1078-0432.CCR-09-175310.1158/1078-0432.CCR-09-1753 ↗
34. 10.1158/0008-5472.CAN-06-080110.1158/0008-5472.CAN-06-0801 ↗
35. 10.3390/ijms23231537410.3390/ijms232315374 ↗
36. Zhao L. · Proc. Natl. Acad. Sci. USA · 2018 · 115
37. 10.1111/j.1600-0625.2006.00502.x10.1111/j.1600-0625.2006.00502.x ↗
38. 10.1016/S1470-2045(18)30483-210.1016/S1470-2045(18)30483-2 ↗
39. 10.7150/jca.3072310.7150/jca.30723 ↗
40. 10.1016/S2666-7568(21)00179-310.1016/S2666-7568(21)00179-3 ↗
41. 10.1007/s00281-018-0697-610.1007/s00281-018-0697-6 ↗
42. 10.1038/s41568-019-0222-910.1038/s41568-019-0222-9 ↗
43. 10.1080/19381980.2016.121539110.1080/19381980.2016.1215391 ↗
44. 10.1001/jamadermatol.2019.335310.1001/jamadermatol.2019.3353 ↗
45. 10.1080/0284186X.2019.164391410.1080/0284186X.2019.1643914 ↗
46. 10.1186/s12967-016-1026-210.1186/s12967-016-1026-2 ↗
47. 10.1001/jamadermatol.2013.70610.1001/jamadermatol.2013.706 ↗
48. 10.7150/jca.2.53810.7150/jca.2.538 ↗
49. 10.1001/archdermatol.2011.26410.1001/archdermatol.2011.264 ↗
50. 10.1245/s10434-015-4538-810.1245/s10434-015-4538-8 ↗
51. 10.1038/nrc323910.1038/nrc3239 ↗
52. 10.3389/fphar.2017.0004910.3389/fphar.2017.00049 ↗
53. 10.1001/jamaoncol.2021.496010.1001/jamaoncol.2021.4960 ↗
54. 10.1016/j.ejca.2018.12.01210.1016/j.ejca.2018.12.012 ↗
55. 10.1634/theoncologist.2016-045010.1634/theoncologist.2016-0450 ↗
56. 10.1200/JCO.2017.75.627010.1200/JCO.2017.75.6270 ↗
57. 10.1158/1078-0432.CCR-18-111610.1158/1078-0432.CCR-18-1116 ↗
58. 10.1001/jamadermatol.2017.458410.1001/jamadermatol.2017.4584 ↗
59. 10.1634/theoncologist.2019-037710.1634/theoncologist.2019-0377 ↗
60. 10.1007/s00262-020-02497-910.1007/s00262-020-02497-9 ↗
61. 10.3389/fimmu.2021.60972810.3389/fimmu.2021.609728 ↗
62. 10.1016/j.critrevonc.2025.10463510.1016/j.critrevonc.2025.104635 ↗
63. 10.3389/fimmu.2022.101963810.3389/fimmu.2022.1019638 ↗
64. 10.3389/fphar.2022.99640410.3389/fphar.2022.996404 ↗
65. 10.3389/fimmu.2024.134818910.3389/fimmu.2024.1348189 ↗
66. 10.1111/cas.1525410.1111/cas.15254 ↗
67. 10.1002/ijc.2933510.1002/ijc.29335 ↗
68. 10.1158/1055-9965.EPI-10-068610.1158/1055-9965.EPI-10-0686 ↗
69. 10.14336/AD.2017.050310.14336/AD.2017.0503 ↗
70. 10.1111/j.1755-148X.2011.00873.x10.1111/j.1755-148X.2011.00873.x ↗
71. 10.1186/s12885-017-3529-510.1186/s12885-017-3529-5 ↗
72. 10.1111/j.1755-148X.2011.00837.x10.1111/j.1755-148X.2011.00837.x ↗
73. 10.1016/j.cell.2015.05.04410.1016/j.cell.2015.05.044 ↗
74. 10.1111/bjd.1250410.1111/bjd.12504 ↗
75. 10.1200/JCO.2010.32.432710.1200/JCO.2010.32.4327 ↗
76. 10.1158/2159-8290.CD-18-019310.1158/2159-8290.CD-18-0193 ↗
77. 10.1158/2159-8290.CD-18-016810.1158/2159-8290.CD-18-0168 ↗
78. 10.1038/nature1739210.1038/nature17392 ↗
79. 10.1158/2159-8290.CD-23-037210.1158/2159-8290.CD-23-0372 ↗
80. 10.1158/2767-9764.CRC-23-017610.1158/2767-9764.CRC-23-0176 ↗
81. 10.62347/QBVC149710.62347/QBVC1497 ↗
82. 10.1016/j.cell.2024.08.01310.1016/j.cell.2024.08.013 ↗
83. 10.1038/s41577-023-00843-310.1038/s41577-023-00843-3 ↗
84. 10.1016/j.cmi.2014.09.01110.1016/j.cmi.2014.09.011 ↗
85. 10.1016/j.mcna.2006.05.01110.1016/j.mcna.2006.05.011 ↗
86. 10.1016/j.jacc.2017.01.06410.1016/j.jacc.2017.01.064 ↗
87. 10.1158/1078-0432.CCR-09-176610.1158/1078-0432.CCR-09-1766 ↗
88. 10.1093/annonc/mdq01310.1093/annonc/mdq013 ↗
89. Nikita N. · Cancers (Basel) · 2022 · 14
90. 10.1158/1078-0432.CCR-21-128310.1158/1078-0432.CCR-21-1283 ↗
91. 10.1002/cncr.3162910.1002/cncr.31629 ↗
92. 10.1186/s12967-024-05617-610.1186/s12967-024-05617-6 ↗
93. 10.1126/science.adf132910.1126/science.adf1329 ↗
94. 10.1126/science.ade852010.1126/science.ade8520 ↗
95. 10.1002/ijc.3208010.1002/ijc.32080 ↗
96. 10.1038/sj.jid.570021110.1038/sj.jid.5700211 ↗
97. 10.1016/j.canlet.2017.09.00510.1016/j.canlet.2017.09.005 ↗
98. 10.1158/0008-5472.CAN-07-281610.1158/0008-5472.CAN-07-2816 ↗
99. Li H. · Cancer Cell · 2022 · 40
100. 10.1111/j.1476-5381.2010.00961.x10.1111/j.1476-5381.2010.00961.x ↗